Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. CureVac N.V.
  6. News
  7. Summary
    CVAC   NL0015436031

CUREVAC N.V.

(CVAC)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

CureVac Says Preclinical Trial Shows Antibody Levels of COVID-19 Vaccine Candidate CV2CoV 'Highly Comparable' With Pfizer's mRNA Vaccine

11/18/2021 | 03:12pm EST


ę MT Newswires 2021
All news about CUREVAC N.V.
07:02aCureVac Chief Technology Officer to Pursue New Career outside Biotech Industry
EQ
01/13CUREVAC N : In relation to the Parties' share portfolios in CureVac N.V. (NL-Amsterdam) - ..
PU
01/03CUREVAC N : Unaudited Interim Condensed Consolidated Balance Sheet and Income Statement as..
PU
2021CureVac Stock Slips Following Kempen's Stock Rating Downgrade
MT
2021Kempen Downgrades CureVac to Sell From Neutral, Adjusts Price Target to $20 From $50
MT
2021CUREVAC N.V.(NASDAQGM : CVAC) added to NASDAQ Biotechnology Index
CI
2021CUREVAC N : Interim Condensed Consolidated Statements of Operations and Other Comprehensiv..
PU
2021CureVac N.V. Reports Earnings Results for the Nine Months Ended September 30, 2021
CI
2021Berenberg Bank Adjusts CureVac's Price Target to $70 From $123, Maintains Buy Rating
MT
2021UK study finds mRNA COVID-19 vaccines provide biggest booster impact
RE
More news
Analyst Recommendations on CUREVAC N.V.
More recommendations
Financials
Sales 2021 - - -
Net income 2021 -428 M -488 M -488 M
Net cash 2021 976 M 1 112 M 1 112 M
P/E ratio 2021 -9,13x
Yield 2021 -
Capitalization 6 719 M 7 669 M 7 661 M
EV / Sales 2021 -
EV / Sales 2022 19,8x
Nbr of Employees 505
Free-Float 45,1%
Chart CUREVAC N.V.
Duration : Period :
CureVac N.V. Technical Analysis Chart | CVAC | NL0015436031 | MarketScreener
Technical analysis trends CUREVAC N.V.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 21,45 €
Average target price 44,43 €
Spread / Average Target 107%
EPS Revisions
Managers and Directors
Franz-Werner Haas Chief Executive Officer
Pierre Kemula Chief Financial Officer & Managing Director
Baron Jean StÚphenne Chairman-Supervisory Board
Mariola Fotin-Mleczek Chief Technology Officer
Igor Splawski Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
CUREVAC N.V.-28.65%7 669
MODERNA, INC.-19.39%83 008
LONZA GROUP AG-15.15%52 584
IQVIA HOLDINGS INC.-12.33%47 252
SEAGEN INC.-11.33%25 068
ICON PUBLIC LIMITED COMPANY-13.98%21 684